Home Upload Photo Upload Videos Write a Blog Analytics Messaging Streaming Create Adverts Creators Program
Bebuzee Afghanistan Bebuzee Albania Bebuzee Algeria Bebuzee Andorra Bebuzee Angola Bebuzee Antigua and Barbuda Bebuzee Argentina Bebuzee Armenia Bebuzee Australia Bebuzee Austria Bebuzee Azerbaijan Bebuzee Bahamas Bebuzee Bahrain Bebuzee Bangladesh Bebuzee Barbados Bebuzee Belarus Bebuzee Belgium Bebuzee Belize Bebuzee Benin Bebuzee Bhutan Bebuzee Bolivia Bebuzee Bosnia and Herzegovina Bebuzee Botswana Bebuzee Brazil Bebuzee Brunei Bebuzee Bulgaria Bebuzee Burkina Faso Bebuzee Burundi Bebuzee Cabo Verde Bebuzee Cambodia Bebuzee Cameroon Bebuzee Canada Bebuzee Central African Republic Bebuzee Chad Bebuzee Chile Bebuzee China Bebuzee Colombia Bebuzee Comoros Bebuzee Costa Rica Bebuzee Côte d'Ivoire Bebuzee Croatia Bebuzee Cuba Bebuzee Cyprus Bebuzee Czech Republic Bebuzee Democratic Republic of the Congo Bebuzee Denmark Bebuzee Djibouti Bebuzee Dominica Bebuzee Dominican Republic Bebuzee Ecuador Bebuzee Egypt Bebuzee El Salvador Bebuzee Equatorial Guinea Bebuzee Eritrea Bebuzee Estonia Bebuzee Eswatini Bebuzee Ethiopia Bebuzee Fiji Bebuzee Finland Bebuzee France Bebuzee Gabon Bebuzee Gambia Bebuzee Georgia Bebuzee Germany Bebuzee Ghana Bebuzee Greece Bebuzee Grenada Bebuzee Guatemala Bebuzee Guinea Bebuzee Guinea-Bissau Bebuzee Guyana Bebuzee Haiti Bebuzee Honduras Bebuzee Hong Kong Bebuzee Hungary Bebuzee Iceland Bebuzee India Bebuzee Indonesia Bebuzee Iran Bebuzee Iraq Bebuzee Ireland Bebuzee Israel Bebuzee Italy Bebuzee Jamaica Bebuzee Japan Bebuzee Jordan Bebuzee Kazakhstan Bebuzee Kenya Bebuzee Kiribati Bebuzee Kuwait Bebuzee Kyrgyzstan Bebuzee Laos Bebuzee Latvia Bebuzee Lebanon Bebuzee Lesotho Bebuzee Liberia Bebuzee Libya Bebuzee Liechtenstein Bebuzee Lithuania Bebuzee Luxembourg Bebuzee Madagascar Bebuzee Malawi Bebuzee Malaysia Bebuzee Maldives Bebuzee Mali Bebuzee Malta Bebuzee Marshall Islands Bebuzee Mauritania Bebuzee Mauritius Bebuzee Mexico Bebuzee Micronesia Bebuzee Moldova Bebuzee Monaco Bebuzee Mongolia Bebuzee Montenegro Bebuzee Morocco Bebuzee Mozambique Bebuzee Myanmar Bebuzee Namibia Bebuzee Nauru Bebuzee Nepal Bebuzee Netherlands Bebuzee New Zealand Bebuzee Nicaragua Bebuzee Niger Bebuzee Nigeria Bebuzee North Korea Bebuzee North Macedonia Bebuzee Norway Bebuzee Oman Bebuzee Pakistan Bebuzee Palau Bebuzee Panama Bebuzee Papua New Guinea Bebuzee Paraguay Bebuzee Peru Bebuzee Philippines Bebuzee Poland Bebuzee Portugal Bebuzee Qatar Bebuzee Republic of the Congo Bebuzee Romania Bebuzee Russia Bebuzee Rwanda Bebuzee Saint Kitts and Nevis Bebuzee Saint Lucia Bebuzee Saint Vincent and the Grenadines Bebuzee Samoa Bebuzee San Marino Bebuzee São Tomé and Príncipe Bebuzee Saudi Arabia Bebuzee Senegal Bebuzee Serbia Bebuzee Seychelles Bebuzee Sierra Leone Bebuzee Singapore Bebuzee Slovakia Bebuzee Slovenia Bebuzee Solomon Islands Bebuzee Somalia Bebuzee South Africa Bebuzee South Korea Bebuzee South Sudan Bebuzee Spain Bebuzee Sri Lanka Bebuzee Sudan Bebuzee Suriname Bebuzee Sweden Bebuzee Switzerland Bebuzee Syria Bebuzee Taiwan Bebuzee Tajikistan Bebuzee Tanzania Bebuzee Thailand Bebuzee Timor-Leste Bebuzee Togo Bebuzee Tonga Bebuzee Trinidad and Tobago Bebuzee Tunisia Bebuzee Turkey Bebuzee Turkmenistan Bebuzee Tuvalu Bebuzee Uganda Bebuzee Ukraine Bebuzee United Arab Emirates Bebuzee United Kingdom Bebuzee Uruguay Bebuzee Uzbekistan Bebuzee Vanuatu Bebuzee Venezuela Bebuzee Vietnam Bebuzee World Wide Bebuzee Yemen Bebuzee Zambia Bebuzee Zimbabwe
Blog Image

Recovery of mice raises hopes drug could help people with spinal injuries

Condition of rodents with spinal cord damage improved after they had lung disease drug, say researchers

Mice with spinal cord injuries have shown remarkable recovery after being given a drug initially developed for people with lung disease, researchers have revealed, saying the treatment could soon be tested on humans.

It is thought there are about 2,500 new spinal cord injuries in the UK every year, with some of those affected experiencing full loss of movement as a result. Despite a number of promising areas of research, at present damage to the spinal cord is not reversible.

Now researchers at the University of Birmingham say a drug called AZD1236, initially developed to treat chronic obstructive pulmonary disease in humans, has shown promise in mice with spinal cord compression injuries, a type of injury often associated with motor accidents in humans, but which is also linked to conditions such as osteoarthritis. A similar drug, called AZD3342, showed comparable benefits in rats.

The results, published in the journal Clinical and Translational Medicine, suggested the drugs block the action of enzymes known as MMP-9 and MMP-12 that rise after spinal cord injury. The upshot was that swelling of the spinal cord was reduced, levels of proteins linked to inflammation and pain were lowered, and breakdown of the blood-spinal cord barrier was limited. Scarring of connective tissue was also reduced.

The team said that compared with injured mice not given AZD1236, those given the drug for three days showed 85% improvement in movement and sensation six weeks after the spinal injury, while their nerve function was 80% of that seen in uninjured mice. Furthermore, the benefits were similar whether the drug was given immediately after spinal injury or 24 hours later.

“What we’re doing is we’re dampening down the damage to the nerve tissues. That way, we’re preserving more and more of the neurons,” said Prof Zubair Ahmed of the University of Birmingham, a co-author of the study.

Ahmed said the findings were exciting, adding that because AZD1236 had already been shown to be safe in humans, it could enter human trials sooner. Read More…

Previous Post

A brain circuit in the thalamus helps us hold information in mind

Next Post

Extinction: Why scientists are freezing threatened species in 'biobanks'

Comments